te Cipla: Today Latest News, Photos, Videos about Cipla - Zee Business

हिंदी में पढ़ें

Cipla

Cipla Shares Slip as Executive Vice-Chair Steps Down | Stock Market News

Cipla Shares Slip as Executive Vice-Chair Steps Down | Stock Market News

Mon, Jan 29, 2024

Shares of Cipla dipped 3% as Samina Hamied resigned as executive vice-chair, transitioning to a non-executive director role. The move is part of a broader strategy to professionalize Cipla's management, akin to conglomerates like the Tata Group. Balram Bhargava was appointed as an additional independent director, bringing over 35 years of global public health leadership experience.

Cipla posts better-than-estimated Q3 results; stock hits all-time high

Cipla posts better-than-estimated Q3 results; stock hits all-time high

Tue, Jan 23, 2024

As of 9:56 a.m., shares of drug major Cipla traded 6.85 per cent or Rs 89.85, higher on the BSE at Rs 1,402.45 apiece. The market capitalisation of the company at around the same time stood at Rs 1,13,227.87 crore.

Cipla Q3 results: 32% rise in net profit to Rs 1,056 crore

Cipla Q3 results: 32% rise in net profit to Rs 1,056 crore

Mon, Jan 22, 2024

The Mumbai-based company had posted a consolidated net profit of Rs 801 crore in the year-ago period, Cipla Ltd said in a statement. Total revenue from operations in the third quarter of the current fiscal rose to Rs 6,604 crore as compared with Rs 5,810 crore in the year-ago period.

TRENDING NOW

Pharma shares in action after Dr Reddy's, Strides Pharma get DCGI nod to launch Molnupiravir

Pharma shares in action after Dr Reddy's, Strides Pharma get DCGI nod to launch Molnupiravir

Wed, Dec 29, 2021

The rise of the Covid-19 variant Omicron has once again brought pharma shares in focus.

Sector Spotlight – Pharma sector in focus on Monday; analyst recommends 3 stocks for gains

Sector Spotlight – Pharma sector in focus on Monday; analyst recommends 3 stocks for gains

Mon, Dec 27, 2021

Spotlight was on Nifty Pharma as the index was the top gainer around this time. It was trading at 13,710.80 and near its intraday high, up 1.6 per cent from the Friday closing level

Cipla receives USFDA nod to market Lanreotide injection in American market

Cipla receives USFDA nod to market Lanreotide injection in American market

Sun, Dec 19, 2021

Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market

Freaky Friday: Markets witness freefall - These stocks led the plunge but pharma scrips shone

Freaky Friday: Markets witness freefall - These stocks led the plunge but pharma scrips shone

Fri, Nov 26, 2021

As the bears grip the market during Friday’s session, metal, auto, and pharma stocks witnessed a maximum buzz. In this regard, JSW Steel, Tata Motors, Hindalco slipped most, while Cipla and Dr Reddy’s were the top gainers in the otherwise negative market.

Cipla Q2FY22 Results: Consolidated Net up 7% at Rs 711 cr amid strong performance

Cipla Q2FY22 Results: Consolidated Net up 7% at Rs 711 cr amid strong performance

Tue, Oct 26, 2021

Drug major Cipla on Tuesday said its consolidated profit after tax (PAT) rose by 7 per cent to Rs 711 crore for the second quarter ending September, aided by strong performance in the domestic as well as international markets.

Lupin, Glenmark, JB chemicals, Cipla, Aurobindo potential winners to ride $183 bn cardiac therapy market

Lupin, Glenmark, JB chemicals, Cipla, Aurobindo potential winners to ride $183 bn cardiac therapy market

Thu, Sep 30, 2021

Cardiovascular disease (CVD) is the leading cause of mortality and accounts for one-third of global deaths. Cardiac has displaced anti-infectives as the leading therapy in the India Pharma Market (IPM).

Nifty Pharma set for 14,600 levels - 3 stocks to buy on Wednesday for gains, says Centrum Broking analyst

Nifty Pharma set for 14,600 levels - 3 stocks to buy on Wednesday for gains, says Centrum Broking analyst

Wed, Sep 29, 2021

Sun Pharmaceuticals – The shares of Sun Pharma today ended at Rs 790.50 on Tuesday, up 3.6 per cent from the Monday closing price. He puts target price at Rs 850-Rs 880 with a stop loss at Rs 755. The stock has seen some correction after attaining a 52-week high of Rs 804.35 on 3 August

Stocks to Buy on Monday – Cipla, Vardhman Textiles, Poly Medicure are intraday F&O, cash market, positional picks for these targets

Stocks to Buy on Monday – Cipla, Vardhman Textiles, Poly Medicure are intraday F&O, cash market, positional picks for these targets

Sun, Sep 19, 2021

Sandeep Jain recommends Cipla as an intraday pick on Monday. This is from the F&O segment. This stock was recommended at Rs 954. He puts the target price at Rs 965 while the stop loss at Rs 947

Cipla gets USFDA nod for generic product

Cipla gets USFDA nod for generic product

Thu, Aug 12, 2021

Drug firm Cipla has received approval from the US health regulator to market Difluprednate Ophthalmic Emulsion in the American market.

Cipla shares hit NEW HIGH as DCGI approves to import Moderna’s Covid vaccine – check what analyst suggests for the stock investors

Cipla shares hit NEW HIGH as DCGI approves to import Moderna’s Covid vaccine – check what analyst suggests for the stock investors

Wed, Jun 30, 2021

As Drugs Controller General of India (DCGI) allowed Cipla to import Moderna’s Covid-19 vaccine, the shares of the pharma major hit a new 52-week high of Rs 997.20 after rallying almost two per cent on the BSE intraday trade on Wednesday. The stock has surged around four per cent since Monday.

GREEN SIGNAL! Cipla gets DCGI nod to import Moderna's Covid vaccine for restricted emergency use in India: Sources

GREEN SIGNAL! Cipla gets DCGI nod to import Moderna's Covid vaccine for restricted emergency use in India: Sources

Tue, Jun 29, 2021

Moderna's vaccine will be the fourth COVID-19 jab to be available in India after Covishield, Covaxin and Sputnik.

Stock Markets CLOSING BELL! BSE Sensex, NSE Nifty 50 close in red; Power Grid, Nestle, Cipla among top gainers; bank, IT, metal stocks fall

Stock Markets CLOSING BELL! BSE Sensex, NSE Nifty 50 close in red; Power Grid, Nestle, Cipla among top gainers; bank, IT, metal stocks fall

Tue, Jun 29, 2021

Stock Markets ended in the red on Tuesday. The BSE Sensex closed at 52,567.30 today, down by over 168 points or 0.3 per cent. Meanwhile, the broader Market NSE Nifty 50 ended at 15,748.45, down by 66 points or 0.4 per cent

Top Stocks to Buy – Amid high market volatility, analyst Sandeep Jain recommends Cipla, Timken India, KEC International for bumper returns

Top Stocks to Buy – Amid high market volatility, analyst Sandeep Jain recommends Cipla, Timken India, KEC International for bumper returns

Sun, Jun 20, 2021

The stock markets on Friday traded with high volatility. The markets opened without much noise and then fell steeply. Nifty 50 had a free fall and touching around levels of 15,450 on the intraday basis which was a crucial level. The previous lifetime was 15,431 and the markets took a support at this level. Market Analyst Sandeep Jain said that last trading session of the week was extremely action packed.

Top gainer on Nifty! Cipla share price up over 2%; Sharekhan says BUY

Top gainer on Nifty! Cipla share price up over 2%; Sharekhan says BUY

Thu, May 20, 2021

Cipla share price: Sharekhan expects Cipla’s topline and PAT to report a CAGR of 11.9% and 23.8%, respectively, over FY2021-FY2023E.

Cipla will maintain its EBITDA at 22% in FY22, says Kedar Upadhye

Cipla will maintain its EBITDA at 22% in FY22, says Kedar Upadhye

Thu, May 20, 2021

Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Swati Khandelwal, Zee Business.

Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye

Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye

Wed, May 19, 2021

Kedar Upadhye, Global Chief Finance Officer, Cipla, talks about March quarter numbers, market share of Albuetrol in the US market, the deal with Eli Lilly for the drug Baricitinib, production of Remedisvir black fungus drug and guidance for FY22 among others during a candid chat with Zee Business Executive Swati Khandelwal

Cipla share price up nearly 2% despite weak markets: Sharekhan maintains Buy, price target of Rs 1100

Cipla share price up nearly 2% despite weak markets: Sharekhan maintains Buy, price target of Rs 1100

Wed, May 19, 2021

Cipla share price: Sharekhan says that Cipla Limited reported strong numbers for Q4FY2021 yoy, though it missed estimates. Results reflect a one time adjustments in gross margins to the tune of 200 bps on account of inventory adjustment for gAlbuterol and charge on material cost inventories. Revenue, at Rs 4606.5 cr, grew by 5% yoy, driven by a 17% rise in US revenues; sales from emerging markets and India grew by 4% yoy each

Cipla Q4 below street estimates: Know what brokerage firms have to say – check target price here

Cipla Q4 below street estimates: Know what brokerage firms have to say – check target price here

Mon, May 17, 2021

Amid the fourth quarter results being sharply below estimates, the brokerage firms post mixed sentiments towards the pharma major Cipla. However, the company reported a 68 per cent jump in the consolidated net profit in the March-ended quarter of the financial year 2020-2021.

Cipla share price: Sharekhan maintains Buy recommendation with price target of Rs 1100

Cipla share price: Sharekhan maintains Buy recommendation with price target of Rs 1100

Mon, May 17, 2021

Cipla share price: Sharekhan says that Cipla Limited reported strong numbers for Q4FY2021 yoy, though it missed estimates. Results reflect a one time adjustments in gross margins to the tune of 200 bps on account of inventory adjustment for gAlbuterol and charge on material cost inventories. Revenue, at Rs 4606.5 cr, grew by 5% yoy, driven by a 17% rise in US revenues; sales from emerging markets and India grew by 4% yoy each

Cipla Q4FY21 net profit up 73% at Rs 412 cr; company board recommends Rs 5 dividend for FY21

Cipla Q4FY21 net profit up 73% at Rs 412 cr; company board recommends Rs 5 dividend for FY21

Fri, May 14, 2021

Drug major Cipla on Friday today posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets. The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x